Gene Therapy EU Country Go-to-Market Model Design

A small biotech was launching its first rare disease gene therapy in Europe. The therapy required highly specialized treatment centers to be administered, and the company needed to define the go-to-market model and key roles.

Our team began by assessing the company’s current business model and priorities. We defined a decision-making framework through a cross-functional working session to align on the key parameters influencing the go-to-market model. We then conducted a landscape assessment to understand the disease area and key stakeholders involved in the patient journey. This was informed by primary research with a wide range of stakeholders in the market ecosystem. Our next task was to develop a patient uptake model to inform the number of treatment centers that needed to be established. Finally, we defined the go-to-market options, prioritized them, and recommended the optimal model.

The company was able to implement the optimal go-to-market model based on its aspirations and the market’s needs